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Abstract
Background: Little is known about the roles of Notch signaling in cholangiocarcinoma (CC). The expression of
hairy and enhancer of split 1 (Hes-1) has not been investigated yet in resected specimens of CC. Notch signaling
has been reported to be related to cancer stem cell (CSC) like properties in some malignancies. Our aim is to
investigate the participation of Notch signaling in resected specimens of extrahepatic CC (EHCC) and to evaluate
the efficacy of CC cells with CSC-like properties by Notch signaling blockade.
Methods: First, the expression of Notch1, 2, 3, 4 and Hes-1 was examined by immunohistochemistry in 132
resected EHCC specimens. The clinicopathological characteristics in the expression of Notch receptors and Hes-1 were
investigated. Second, GSI IX, which is a γ-secretase-inhibitor, was used for Notch signaling blockade in the following
experiment. Alterations of the subpopulation of CD24+CD44+ cells, which are surface markers of CSCs in EHCC, after
exposure with GSI IX, gemcitabine (GEM), and the combination of GSI IX plus GEM were assessed by flow cytometry
using the human CC cell lines, RBE, HuCCT1 and TFK-1. Also, anchorage-independent growth and mice tumorigenicity
in the cells recovered by regular culture media after GSI IX exposure were assessed.
Results: Notch1, 2, 3, 4 and Hes-1 in the resected EHCC specimens were expressed in 50.0, 56.1, 42.4, 6.1, and 81.8 % of
the total cohort, respectively. Notch1 and 3 expressions were associated with poorer histological differentiation (P = 0.008
and 0.053). The patients with the expression of at least any one of Notch1-3 receptors, who were in 80.3 % of the total,
exhibited poorer survival (P = 0.050). Similarly, the expression of Hes-1 tended to show poor survival (P = 0.093). In all of
the examined CC cell lines, GSI IX treatment significantly diminished the subpopulation of CD24+CD44+ cells. Although
GEM monotherapy relatively increased the subpopulation of CD24+CD44+ cells in all lines, GSI IX plus GEM
attenuated it. Anchorage-independent growth and mice tumorigenicity were inhibited in GSI IX-pretreated
cells in RBE and TFK-1 (P < 0.05).
Conclusion: Aberrant Notch signaling is involved with EHCC. Inhibition of Notch signaling is a novel
therapeutic strategy for targeting cells with CSC-like properties.
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Background
Cholangiocarcinoma (CC) arises from epithelial cells
lining the bile duct. The incidence of CC is the highest
in East and South Asia and has been increasing world-
wide [1, 2]. Chronic damage and inflammation of the
biliary epithelium, such as from gallstones, chronic
hepatitis, primary sclerosing cholangitis and liver fluke
infection, are considered risk factors for the formation of
CC [3, 4]. Although various genetic alterations in CC
have been reported [5–7], molecular biological informa-
tion about CC is scant. Complete surgical resection
offers the only chance for cure [8]. Nevertheless, the
prognosis after surgery for CC is poor, especially for
advanced tumors, such as node metastasis and perineu-
ral invasion. The efficacy of chemotherapy for CC, in
which the combination therapy of gemcitabine (GEM)
and cisplatin (CDDP) is now considered the best for ad-
vanced CC [9, 10], is limited in its ability to cure malig-
nancies. Therefore, the emergence of a novel therapeutic
strategy is urgently needed.
Notch signaling is an evolutionarily conserved pathway
that plays an important role in various cellular and de-
velopmental processes [11]. Aberrant activation of Notch
signaling has been shown to be involved in various ma-
lignancies, such as pancreatic cancer, breast cancer, lung
cancer and leukemia [12–15]. Concerning CC, which is
classified into intrahepatic CC (IHCC) or extrahepatic
CC (EHCC) according to the primary site, only a few
reports have demonstrated the aberrant expression of
Notch receptors or ligands by immunohistochemistry
(IHC) using clinically resected specimens of EHCC or
IHCC [16, 17]. In IHCC, the aberrant expressions of
Notch1 and Notch4 were reported to be associated with
cancer progression [16]. On the other hand, the aberrant
expression of Notch1 and 3 correlated with cancer pro-
gression in EHCC [17]. However, in both reports, the
presence of aberrant hairy and enhancer of split 1 (Hes-
1) expression, which is a representative downstream
target gene of Notch signaling, had not been evaluated.
According to recent studies using transgenic mice, con-
secutive Notch1 or 2 signaling induced the formation of
IHCC by the liver progenitor cells [18–20]. Thus, further
studies are needed to elucidate a role of Notch signaling,
including types of Notch receptors, for CC.
Notch signaling is initiated by ligand binding from ad-
jacent cells, followed by intramembranous proteolytic
cleavage of the Notch receptor by the γ-secretase com-
plex and release of the Notch intracellular domain
(NICD). NICD translocates to the nucleus and induces
target genes, such as Hes-1. γ-secretase inhibitor (GSI)
has been reported to have antitumor effects as Notch
antagonism by suppression of the Notch receptor cleav-
age against cancers linked with aberrant activation of
Notch signaling in vitro and in vivo [13, 14, 21, 22].
Clinical trials for GSI for some malignancies are ongoing
[23, 24]. Cancer stem cells (CSCs), which are critical for
tumor initiation, progression and persistence, are con-
sidered to be generally resistant to conventional chemo-
therapy. Notch signaling plays a pivotal role in the
initiation and maintenance of tumor [25–27]. Although
several reports described that blocking Notch signaling
by GSI showed inhibition of cell proliferation and inva-
sion in CC in vitro [28, 29], the efficacy of GSI for CC
cells with CSC-like properties has not been confirmed.
The aim of the present study is two-fold. First, we
investigated the correlation between the expression of
Notch1, 2, 3, 4 or Hes-1 and clinicopathological factors
using resected EHCC specimens. Second, therapeutic
effectiveness of GSI for cells with CSC-like properties
was evaluated using CC cell lines.
Methods
Patient selection and specimens
One hundred thirty-two consecutive patients with surgi-
cally resected EHCC at our institution between 2000
and 2008, who did not receive chemotherapy or radio-
therapy before surgery, were examined in this study. The
medical records including clinicopathological findings
and paraffin-embedded tissues of resected EHCC were
collected for all patients. Pathological diagnosis was
done by two pathologists with expertise in hepato-
biliary-pancreatic pathology. Histological differentiation
and tumor staging were based on the 7th edition of
Union for the International Cancer Control (UICC) clas-
sification. When local recurrence or distant metastasis
was present, chemotherapies and/or radiation therapies
were applied to patients with good performance status
0–2 (Eastern Cooperative Oncology Group, ECOG).
This study was approved by the Institutional Review
Board of Tohoku University. We obtained written in-
formed consent for participation in the study from all of
the patients.
Most patients with EHCC received biliary drainage
due to biliary obstruction during the preoperative
period. Biliary drainage generally causes inflammatory
changes of non-neoplastic cholangiocytes, which often
induces the expression of Notch receptors in it [17, 30].
Therefore, normal bile duct tissues of 8 patients with
pancreatic neuroendocrine tumors (pNET) who under-
went pancreaticoduodenectomy were assessed as con-
trols. Survival analysis was performed in patients with
R0 resection.
Immunohistochemistry (IHC)
IHC was performed using antibodies of Notch1 (sc-
6014, dilution 1:100, Santa Cruz Biotechnology, Inc., TX,
USA), Notch2 (sc-5545, dilution 1:200, Santa Cruz Bio-
technology, Inc.), Notch3 (sc-5593, dilution 1:500, Santa
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Cruz Biotechnology, Inc.), and Notch4 (sc-5594, dilution
1:200, Santa Cruz Biotechnology, Inc.) receptors and
Hes-1 (ab49170, dilution 1:200, Abcam plc, Cambridge,
UK). Concerning the immunostaining method by anti-
bodies of Notch1, 2, 3 and 4, the streptavidin-biotin
(SAB) method was applied. Briefly, sections of 2 μm
thick from a paraffin-embedded tissue blocks were
deparaffinized in xylene for 10 min, rehydrated using a
graded alcohol series, placed in an endogenous peroxide
blocker for 10 min and washed with buffer. The slides
were microwaved for 15 min (Notch1), autoclaved for
5 min (Notch2 and 3) or trypsinized for 30 min
(Notch4) for antigen retrieval. Primary antibodies of
Notch1, 2, 3 and 4 were applied overnight at 4 °C
and antibody binding was detected using biotinylated
anti-goat or anti-rabbit IgG conjugating streptavidin-
peroxidase complex (BA-9500, Vector Laboratories,
CA, USA) (Histofine SAB-PO® kit, Nichirei Bio-
science Inc., Tokyo, Japan) for 30 min. Finally, the
sections were developed with 3,3′-diaminobenzidine
color solution for 3 min at room temperature. Then,
hematoxylin was used as a chromogen and the slides
were consecutively counter-stained for 60 s.
Interpretation for IHC
Although Notch1, 2, 3 and 4 were stained very weakly in
the non-neoplastic biliary cytoplasm of some cases, the
cytoplasmonuclear coexistent localization of Notch re-
ceptors (Fig. 1a: arrow) was defined as positive staining,
as like the previous report [17]. Only either the cytoplas-
mic or nuclear stained cases were defined as negative.
The cases with nuclear expression of Hes-1 in more
than 70 % of the tumor cells per tumor were defined as
positive. Witten informed consent for the publication of
Fig. 1a was obtained from all of the patients.
Cell culture
Human CC cell lines (RBE, HuCCT1 and TFK-1) were
used for this study. RBE was obtained from RIKEN Bio
Resource Center (Tsukuba, Japan). HuCCT1 and TFK-1
were obtained from the Cell Resource Center for Bio-
medical Research of Tohoku University. All cell lines
were cultured in RPMI 1640 medium (Sigma Aldrich,
MO, USA) supplemented with 10 % heat-inactivated
fetal bovine serum (FBS) (Sigma Aldrich) and 1 %
penicillin/streptomycin (Thermo Fisher Scientific Inc.,
MA, USA) at 37 °C in 5 % CO2.
Drugs and treatment in vitro
GSI IX (Merck Millipore, MA, USA) was prepared as a
10 mM stock solution in dimethyl sulfoxide (DMSO)
(Wako Pure Chemical Industries, Ltd., Osaka, Japan)
and was diluted with media before the treatment in
vitro. Cells were treated with GSI IX (20 or 40 μM) or
DMSO as a control and then analyzed. GEM (LKT
Laboratories, Inc., MN, USA) was used at 40nM in solu-
tion with phosphate buffered saline (PBS).
Quantitative real-time reverse transcription polymerase
chain reaction (qPCR)
Cells cultured with GSI IX or DMSO for 72 h were then
evaluated. Total RNA was isolated using NucleoSpin RNA
II (Takara Bio Inc., Shiga, Japan) and analyzed by nanodrop
(Thermo Fisher Scientific Inc.). qPCR was carried out using
StepOnePlus real-time PCR system (Thermo Fisher Scien-
tific Inc.) using SYBR Premix Ex Taq II (Tli RNaseH Plus)
(Takara Bio Inc.). GAPDH was used as a housekeeping
gene. qPCR was done at the annealing temperature of 60 °
C with the following primers for GAPDH: 5′-GCACCGT
CAAGGCTGAGAAC-3′ for sense and 5′-TGGTGAA
GACGCCAGTGGA-3′ for antisense and for Hes-1: 5′-
TCAGCTGGCTCAGACTTTCA-3′ for sense and 5′-
TCAACACGACACCGGATAAA-3′ for antisense. Relative
amount of mRNA was calculated by the 2−ΔΔCT method.
Protein extraction and Western blotting
Cells cultured with GSI IX or vehicle for 96 h were lysed
in lysis buffer containing 1 mM Phenylmethanesulfonyl
Fluioride (PMSF) (Cell signaling technology Inc., MA,
USA). For immunoblotting, the cell lysates were loaded
on a 4 to 15 % sodium dodecyl sulfate (SDS)-polyacryl-
amide gel at equal amounts of protein (20 μg) per well
and transferred to Polyvinylidenefluoride (PVDF) mem-
branes using Trans-Blot Turbo Blotting System (Bio-
Rad, CA, USA). The membranes were blocked using
SuperBlock (TBS) Blocking Buffer (Thermo Fisher Sci-
entific Inc.) for 1 h at room temperature. Then, they
were probed with primary antibodies against cleaved
Notch 1 (#4147, dilution 1:1000, Cell signaling technol-
ogy Inc.), Hes-1 (#11988, dilution 1:1000, Cell signaling
technology Inc.) and GAPDH (#5174, dilution 1:1000;
Cell signaling technology Inc.). The signals were
detected by Clarity Western ECL Substrate (Bio-Rad)
according to the manufacturer’s instructions.
Proliferation assay
In order to investigate the effect of GSI IX on cell prolif-
eration, cells were plated at a concentration of 1 × 103
cells/well in a 96 well plate overnight. Afterward, cells
were treated with DMSO, different concentrations of
GSI IX (20 and 40 μM) and combination of GSI IX
(40 μM) and GEM (40nM), and measured at different
time points (1–4 days). At the respective time point,
10 μL water-soluble tetrazodium salt (Cell Counting Kit-
8 Reagent) (DOJINDO LABORATORIES, Kumamoto,
Japan) was added to each well and incubated for 2 h at
37 °C. The absorbance was detected at a wavelength of
490 nm.
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Flow cytometric analyses
Flow cytometric analysis was performed using a FAC-
SAria II (Becton Dickinson Biosciences, CA, USA), with
antibodies CD24-BV421 and CD44-APC (BD Biosci-
ences), previously described [31]. In brief, dissociated
cells were counted at a concentration of 106 cells per
100 μL in a 5 ml tube, washed and resuspended in PBS
buffer containing 0.5 % bovine serum albumin (BSA)
and 2 mM ethylenedinitrilotetraacetic acid (EDTA). Cells
with higher-expressing levels of CD24 or CD44 than
those seen in IgG controls (BD Biosciences) were con-
sidered positive. Side scatter and forward scatter profiles
were used to eliminate cell doublets. Cells were exposed
with DMSO, GSI, GEM or GSI plus GEM for 96 h. Ex-
periments were repeated three times for each line.
Anchorage-independent growth
The anchorage-independent growth of cells was investi-
gated using soft agar assays. Briefly, cells were incubated
in media containing 0.5 % FBS with DMSO or GSI IX
(20 or 40 μM) for 96 h. Afterward, the treated cells were
recovered from the media with 10 % FBS for 24 h. Then,
1 × 104 viable cells from each condition were seeded in 6-
well plates for soft agar assays. Viable cells were quantified
using a hemocytometer with trypan blue counterstain. A
bottom layer of 1 % agarose (Thermo Fisher Scientific
Inc.), a middle layer of 0.6 % agarose and a top layer of
medium alone were applied in each well. After incubating
the plates for 8 weeks, colonies were stained with crystal
violet solution and quantified by counting the number of
colonies in 9 random fields at 5× magnification.
Engraftment of ex vivo pretreated CC cells in
immunodeficiency mice
All animal experiments conformed to the guidelines of
the Institutional Animal Care and Use Committee of
Tohoku University and were performed in accordance
with the Guide for the Care and Use of Laboratory
Animals of Tohoku University.
Nonobese diabetic/severe combined immunodeficiency
(NOD/SCID) female mice were purchased from CLEA
Japan, Inc. (Tokyo, Japan). CC cell lines were pretreated
ex vivo with media containing 0.5 % FBS with DMSO or
GSI IX (40 μM) for 96 h, followed by recovery in full
serum conditions for an additional 24 h before subcuta-
neous implantation. Viable 3 × 106 cells in a total volume
of 200 μL of 1:1 (v/v) PBS/Matrigel (BD Biosciences)
were subcutaneously inoculated into bilateral flanks
(right flank: DMSO-pretreated cells, left flank: GSI IX-
pretreated cells) of mice (N = 6). These tumors were
measured every 10 days using an electronic caliper
(A&D Company Ltd., Tokyo, Japan). The tumor volume
was calculated using the following formula [31]: Tumor
Size = [Length ×Width2]/2.
Statistical analysis
The χ2 test was used to compare categorical variables
and the Kaplan-Meier method was used to generate sur-
vival curves. The association between clinicopathological
factors and Notch receptors/Hes-1 was assessed with
the Pearson correlation coefficient. Analyzed data were
described as the mean ± S.E. A Wilcoxon test was used
for statistical analysis with JMP Pro 11.2.0 (SAS Institute
Inc., NC, USA). Significant difference between experi-
mental groups was determined as a P-value < 0.05.
Results
Clinicopathological characteristics of patients
One hundred thirty-two patients with EHCC, compris-
ing 92 men and 40 women (median age: 68 y.o.), were
diagnosed with 83 perihilar and 49 distal CC. Among
the 132 patients, pathological arterial and portal invasion
was observed in 6 and 22 patients, respectively
(Table 1). According to the histological differentiation,
the number of patients with grade 2 (n = 100: 75.8 %)
was the highest. Lymph node metastases were ob-
served in 91 patients (68.9 %). The number of patients
with Stage I, II, III and IV were 20 (15.2 %), 57
(43.2 %), 18 (13.6 %) and 37 (28.0 %), respectively. R0
resection was achieved in 98 patients (74.2 %).
Expression of Notch receptors and Hes-1 in the resected
specimens
Of 132 resected EHCC specimens, there was positive
immunostaining of Notch1, 2, 3, 4 and Hes-1 in 66
(50.0 %), 74 (56.1 %), 56 (42.4 %), 8 (6.1 %) and 108
(See figure on previous page.)
Fig. 1 IHC of Notch receptors and Hes-1 in resected EHCC specimen. a Representative photographs of IHC. 1), 2), 3), 4) and 5) are Notch1, 2, 3, 4
and Hes-1, respectively, in the EHCC. 6) and 7) are Notch1 and Hes-1, respectively, in the normal bile duct of resected pNET specimens. Although
Notch1, 2, 3, 4 and Hes-1 were stained very weakly in the non-neoplastic biliary cytoplasm or nuclear (a-5,6), the cytoplasmonuclear coexistent
localization of Notch receptors (arrow) was defined as positive staining (a-1-4). The cases with nuclear expression of Hes-1 in more than 70 % of
the tumor cells per tumor were defined as positive (a-5). b Expression rate of Notch receptors and Hes-1 in EHCC and normal bile ducts. Of 132
resected EHCC specimens, there was positive immunostaining of Notch1, 2, 3, 4 and Hes-1 in 66 (50.0 %), 74 (56.1 %), 56 (42.4 %), 8 (6.1 %) and 108
(81.8 %) specimens, respectively, and cases with positive immunostaining in at least any one of Notch1, 2 and 3 were shown in 106 specimens
(80.3 %). c Overall survival curve of EHCC patients with R0 resection. Patients with at least one expression of any Notch1-3 exhibited poorer prognosis
than those with no expression of Notch1, 2 or 3 (3-years OS: 57.6 % vs 70.2 %, P = 0.050). Hes-1 expression tended to be related to poorer prognosis
(3-years OS: 55.1 % vs 82.6 %, P = 0.093)
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(81.8 %) specimens, respectively, and cases with positive
immunostaining in at least any one of Notch1, 2 and 3
were shown in 106 specimens (80.3 %) (Fig. 1b). On the
other hand, in normal cholangiocytes of resected pNET
specimens, no positive immunostaining of Notch1, 2, 3,
4 and Hes-1 was observed (Fig. 1a6)7), b).
Clinicopathological factors and prognosis in expressions
of Notch receptors and Hes-1
The number of patients with Notch1 expression was
significantly greater in those with Grade 2/3 than Grade
1 (P = 0.008) (Table 2). Cases with the expression of
Notch3 were also significantly more common in Grade
2/3 than in Grade 1 (P = 0.053). In terms of the Tumor
category, T1/2 was higher than T3/4 in the expression of
Noch3 (P = 0.049). According to the stage classification,
there was no significant difference in the expression of
any Notch receptors and Hes-1. 92 specimens of cases
with at least one expression of Notch1, 2 and 3 (86.8 %)
also showed positive staining of Hes1 and there was
significant correlation between them (P = 0.005). By
Pearson’s correlation analysis, there was no significant
correlation between the clinicopathological factors and
expression of Notch receptors/Hes-1.
In the 98 patients with R0 resection, there was no sig-
nificant survival difference between patients with and
without the expression of each Notch receptor (data not
shown). However, those with at least one expression of
Notch1, 2 and 3 exhibited a poorer prognosis than those
with no expression of Notch1, 2 or 3 (3-years overall
survival (OS): 57.6 % vs 70.2 %, P = 0.050) (Fig. 1c). Simi-
larly, patients with Hes-1 expression tended to show a
worse prognosis than those without Hes-1 expression
(3-years OS: 55.1 % vs 82.6 %, P = 0.093).
Inhibition of Notch signaling and proliferation in CC cells
treated with GSI
To determine whether GSI could modulate Notch
target genes, we assessed the alteration of Hes-1 ex-
pression in the CC cells lines by qPCR and Western
Blotting. As illustrated in Fig. 2a, b, cleaved Notch1
(Notch1 intracellular domain: N1ICD) and Hes-1
expression was decreased in all cell lines treated with
GSI IX, especially after exposure to 40 μM of GSI IX.
Next, the effect of GSI IX on the proliferation of CC
cell lines was determined by CCK-8 assay. GSI IX
significantly reduced viable RBE, HuCCT1 and TFK-1
cells in a dose and time dependent manner (P < 0.05)
(Fig. 2c). These results demonstrated that Notch sig-
naling was related to the proliferation of CC cells. In
the proliferation of CC cells, the combination therapy
of GSI (40 μM) and GEM (40nM) significantly re-
duced viable RBE and TFK-1 cells compared with
GEM monotherapy (Fig. 3).
Alteration of subpopulation of CD24+CD44+ cells by GSI
We assessed the alteration in the subpopulation of
CD24+CD44+ cells by treatment with GSI IX (Fig. 4a, b).
Cells with CD24+CD44+ after treatment with DMSO
were 21.5 %. The subpopulation of CD24+CD44+ cells
after treatment with 20 and 40 μM of GSI IX were
significantly decreased to 7.0 and 5.0 %, respectively, in
RBE cell lines, compared to control (21.5 %) (P < 0.05).
In the other CC cell lines, GSI treatment also decreased
the subpopulation of CD24+CD44+ cells (Fig. 4b).
In contrast, the subpopulation of CD24+CD44+ cells
increased to 28.3 % after monotherapy with GEM in
RBE cell lines. The combination with GSI IX and GEM
significantly diminished the subpopulation to 22.1 %
(P < 0.05) (Fig. 4c). The results of GEM monotherapy
or combination of GSI IX and GEM were consistent in
the other CC cell lines (Fig. 4d).
Table 1 Clinicopathological factors of EHCC patients
Number Percent
Total 132 100.0 %
Age Median 68
Range 15–83
Gender Male 92 69.7 %
Female 40 30.3 %
Location Perihilar 83 62.9 %
Distal 49 37.1 %
Arterial invasion Yes 6 4.5 %
No 126 95.5 %
Portal invasion Yes 22 16.7 %
No 110 83.3 %
Histopathological grading 1 20 15.2 %
2 100 75.8 %
3 12 9.1 %
Tumor 1 4 3.0 %
2 63 47.7 %
3 34 25.8 %
4 31 23.5 %
Node 1 91 68.9 %
0 41 31.1 %
Stage I 20 15.2 %
II 57 43.2 %
III 18 13.6 %
IV 37 28.0 %
Residual tumor classification 0 98 74.2 %
1 or 2 34 25.8 %
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Anchorage-independent growth and mice tumorigenicity
of GSI-pretreated cells
To confirm the effectiveness of treatment with GSI
on cells with CSC-like properties, we investigated
the alteration of anchorage-independent growth and
mice tumorigenicity after pretreatment with GSI IX
(Fig. 5a–d). The ability to form clones in soft agar
was inhibited more strongly by the pretreatment of
GSI IX 20 μM and 40 μM, compared with DMSO-
pretreated cells in RBE and TFK-1 (Fig. 5a, b).
HuCCT1 cells did not form any colonies in soft agar
after DMSO or GSI IX pretreatment (data not
shown). As with the results of the anchorage-
independent growth, the mice tumorigenicity of cells
pretreated with GSI IX was significantly attenuated
in all cell lines compared to DMSO (Fig. 5c, d).
Discussion
Recently, several reports have discussed the participa-
tion of Notch signaling in CC [18–20]. However, the
roles of Notch signaling in CC have not been fully
understood. In the current study, IHC of resected
Table 2 Expression of Notch receptors and Hes-1 in EHCC patients
Notch1 Notch2
+ − p r2 + − p r2
Total (%) 66 (50.0) 66 (50.0) 74 (56.1) 58 (43.9)
Histopathological grading G1 5 16 0.008 0.186 10 11 0.397 0.019
G2/3 61 50 64 47
Tumor 1/2 35 32 0.259 0.089 36 31 0.584 0.067
3/4 31 34 38 27
Node 0 46 46 1.000 0.000 49 43 0.324 0.066
1 20 20 25 15
Stage I/II 41 36 0.377 −0.086 39 38 0.776 0.123
III/IV 25 30 35 20
Notch3 Notch4
+ − p r2 + − p r2
Total (%) 56 (42.4) 76 (57.6) 8 (6.1) 124 (93.9)
Histopathological grading G1 5 16 0.053 0.186 0 21 0.090 0.161
G2/3 52 59 8 103
Tumor 1/2 34 33 0.049 −0.134 5 62 0.491 0.007
3/4 22 43 3 62
Node 0 36 56 0.247 0.091 5 87 0.654 0.040
1 20 20 3 37
Stage I/II 33 44 0.929 0.013 4 73 0.624 0.049
III/IV 24 31 4 51
Notch1-3 Hes1
+ − p r2 + − p r2
Total (%) 106 (80.3) 26 (19.7) 108 (81.8) 24 (18.2)
Histopathological grading G1 15 6 0.283 0.056 16 4 0.951 0.022
G2/3 91 20 92 20
Tumor 1/2 52 15 0.430 0.043 54 13 0.712 0.079
3/4 54 11 54 11
Node 0 71 21 0.156 0.119 73 19 0.371 0.097
1 35 5 35 5
Stage I/II 59 18 0.202 0.130 60 17 0.163 0.058
III/IV 47 8 48 7
P value: χ2 test
r2 value: Pearson correlation coefficient
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EHCC specimens demonstrated aberrant expression of
Notch1, 2 or 3 in approximately 40–60 % of the co-
hort and that of Hes-1 was found in approximately
80 %. This is the first report on aberrant Hes-1 ex-
pression in resected CC specimens. According to the
confirmation of the Hes-1 expression, the activated
Notch signaling in EHCC was endorsed. Moreover,
the results of IHC implied that the expressions of
Notch1 and 3 were associated with poorer histologic
differentiation. Although there was no significant
prognostic difference in the expression of each
Notch receptor, the patients with the expression of
at least any one of the Notch1, 2 and 3 tended to
exhibit poorer survival, as well as those with the
expression of Hes-1. Therefore, aberrant Notch sig-
naling might be an indicator of poor survival. Yoon
et al. reported the up-regulation of Notch1 and 3 in
the progression of tumor stage in EHCC [17]. How-
ever, in our study, Notch1, 2, 3 and Hes-1 were not
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Fig. 2 Alteration of Hes-1 expression and cell proliferation by GSI IX treatment in vitro. a qPCR. b Western blotting. Cleaved Notch1 (N1ICD) and
Hes-1 expression was decreased in all cell lines treated with GSI IX, especially after exposure to 40 μM of GSI IX (a, b). c Proliferation Assay. GSI IX
significantly reduced viable RBE, HuCCT1 and TFK-1 cells in a dose and time dependent manner (P < 0.05)
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imply that Notch signaling participates in the initial
step. Yoon et al. also described the high immunopo-
sitivity of Notch4 in EHCC [17], whereas our results
showed very low positivity. Wu et al. described that
positive immunostaining of Notch1 and 4 in IHCC
were detected in 82.9 and 34.1 %, respectively, and
were related to the tumor progression [16]. On the
other hand, Notch1 and 2 were reported to play
important roles in tumor proliferation and invasion
in IHCC cell lines [18–20, 28, 29]. Accordingly, the
types of Notch receptors involved in CC differ
between the previous reports and the current study,
the reason for which needs to be clarified in further
studies.
GSI inhibits the γ-secretase-dependent cleavage of all
Notch receptors as a pan-Notch inhibitor. GSI induces
apoptosis through the regulation of nuclear factor-κB
[32] and inhibits cancer cell growth and invasion. The
effectiveness of GSI on cells with CSC-like properties
has been reported in pancreatic cancer, breast cancer
and brain tumor [21, 22, 33, 34]. Also, preclinical evi-
dence in vivo has been demonstrated in some malignan-
cies [21, 22]. A recent report clarified that CD24+CD44+
cells showed CSC-like properties in EHCC [35]. In this
study, GSI exposure diminished the subpopulation of
CD24+CD44+ in all CC cell lines and induced a signifi-
cant reduction of anchorage-independent growth and
delayed tumor engraftment in mice. The present study
first elucidated the therapeutic effect of GSI on CC cells
with CSC-like properties, similar to the effect found in
other cancers.
The CSCs hypothesis is based on the idea that can-
cer tissue has a minute proportion of cells with stem
cell-like properties, which possess a great ability for
self-renewal and produce heterogeneous progeny.
CSCs, which drive tumorigenesis and maintain tumor
proliferation, are located at the top of a hierarchy of
tumor cells [25–27]. Cells with CSC-like properties
are activated after hypoxia exposure [36, 37], which is
closely associated with multiple pathological microen-
viroments of CC, and considered to be resistant to
conventional anticancer therapies. To fail to eradicate
cells with CSC-like properties ultimately results in
relapse even when conventional therapy shows a
dramatic effect. Hence, in addition to conventional
therapies, the successful eradication of cells with CSC-
like properties is needed. The systematic chemother-
apy of GEM plus CDDP is now proposed as the most
promising therapy for unresectable CC [9, 10]. This
study showed resistance to GEM in CC cells with
CSC-like properties. In a previous report, pancreatic
cancer cells with CSC-like properties had resistance to
GEM in a patient-derived xenograft model [38].
Although GEM is suggested to be generally ineffective
against cells with CSC-like properties, the combin-



































































: GEM(40nM) + GSI IX(40µM)
* P<0.05 (vs Control)    
# P<0.05 (vs GEM)
#
#
Fig. 3 Alteration of cell proliferation by GSI IX treatment in the CC cell lines. The combination treatment of GSI IX and GEM significantly reduced
viable RBE and TFK-1 cells compared with GEM monotherapy
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subpopulation of CD24+CD44+ cells compared with
GEM alone. Combination therapy of GEM plus GSI
was reported to show a synergy effect in pancreatic
cancer xenograft [21, 22]. Moreover, a recent report
described that treatment of lung cancer with erlotinib,
which is an epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors, resulted in dramatic cell
death and paradoxical enrichment of cells with CSC-
like properties through EGFR-dependent Notch signal
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*                *               *            *              *                *            *               *                *            
21.5% 5.5%
28.3% 22.1%
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Fig. 4 Alteration of subpopulation of CD24+CD44+ cells by GSI IX treatment in the CC cell lines. a Representative data in RBE cells treated with
DMSO or GSI IX. b Percentage of CD44+CD24+ subpopulation in the CC cell lines exposed to GSI IX. The subpopulation of CD24+CD44+ cells after
treatment with 20 and 40 μM of GSI IX were significantly decreased to 7.0 and 5.0 %, respectively, in RBE cell lines, compared to control (21.5 %)
(P < 0.05). In the other CC cell lines, GSI treatment also decreased the subpopulation of CD24+CD44+ cells. c Representative data in RBE cells
treated with DMSO, GSI IX, GEM or combination of GSI IX and GEM. d Percentage of CD44+CD24+ subpopulation in the CC cell lines treated with
DMSO, GSI IX, GEM, or combination of GSI IX and GEM. The subpopulation of CD24+CD44+ cells increased to 28.3 % after monotherapy with
GEM. The combination with GSI IX and GEM significantly diminished the subpopulation to 22.1 % (P < 0.05). The results of GEM monotherapy or
combination of GSI IX and GEM were consistent in the other CC cell lines
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induced resistance because of its cross-regulation with
other oncogenic pathways. Therefore, additional GSI
treatment has potential as a new therapeutic strategy
in CC.
Conclusions
Aberrant Notch signaling is involved in EHCC. In CC,
inhibition of Notch signaling could be a novel therapeutic
strategy for targeting cells with CSC-like properties.
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Fig. 5 Anchorage-independent growth and mice tumorigenicity in the CC cell. lines pretreated with GSI IX ex vivo. a Colony formation in soft
agar in RBE cells. b Normalized colony counts in RBE and TFK-1 cells pretreated with GSI IX. Pretreatment with both 20 and 40 μM of GSI IX significantly
inhibited colony formations in the CC cell lines (P < 0.05). HuCCT1 cells did not form any colonies in soft agar after DMSO or GSI IX pretreatment (data
not shown). c Representative photograph of engraftments of TFK-1 cells pretreated with GSI IX in NOD/SCID mice. Solid and dotted line arrow indicates
GSI IX and DMSO, respectively. d Tumor growth curves of mice implantation in the CC cell lines with pretreatment of DMSO and GSI IX, respectively.
Mice tumorigenicity in GSI IX pretreatment significantly delayed in all cell lines, compared to DMSO
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